Previous 10 | Next 10 |
ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Sight Sciences, Inc. (“Sight Sciences” or “the Company”) (NASDAQ: SGHT) complied with federal securities laws. On September 11, 2023, Sight Sciences announced its third quarte...
2023-09-12 08:42:44 ET Losers: Acelyrin ( SLRN ) -56% announces top-line results from placebo-controlled clinical trial of Izokibep for moderate-to-severe Hidradenitis Suppurativa. Sight Sciences ( SGHT ) -31% on updated guidance . Super League Gaming (...
2023-09-12 06:14:55 ET Related stories Compare metrics for HUMA to ORCL, SGHT, SLRN, WRK WestRock: Solid Asset-Based, But (Likely) Not The Right Time Reevaluating Acelyrin: The Impact Of Mixed Izokibep Results (Rating Downgrade) Oracle Corporation ( ORCL ...
2023-09-12 06:08:49 ET More on Sight Sciences Sight Sciences: Staying Bullish After Q2 Results Beat Sight Sciences cut to Neutral at Citi on reimbursement uncertainty For further details see: Sight Sciences down 28% on updated guidance
2023-09-11 17:20:07 ET Gainers: Matrix Service ( MTRX ) +10% . Adeia ( ADEA ) +7% . Allakos ( ALLK ) +5% . Nurix Therapeutics ( NRIX ) +5% . ADMA Biologics ( ADMA ) +4% . Losers: ACELYRIN ( SLRN ) ...
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patient...
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patient...
MENLO PARK, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients...
2023-08-07 14:00:05 ET Summary Sight Sciences' Q2 2023 financial performance came in above Wall Street analysts, and SGHT's stock price rose by +7.6% last Friday following its results announcement. SGHT's key markets, glaucoma and dry eye, have addressable markets worth billions o...
2023-08-06 07:32:09 ET Sight Sciences, Inc. (SGHT) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Philip Tailor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Ali Bauerlein - Chief Financial Officer ...
News, Short Squeeze, Breakout and More Instantly...
MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of c...
2024-06-17 00:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of ...